464924-27-4

464924-27-4 structure

Name: SLLK, Control Peptide for TSP1 Inhibitor
Chemical Name: (2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-1,3-dihydroxy-propylidene]amino]-1-hydroxy-4-methyl-pentylidene]amino]-1-hydroxy-4-methyl-pentylidene]amino]hexanoic acid
CAS Number: 464924-27-4
Molecular Formula: C₂₁H₄₁N₅O₆
Molecular Weight: 459.580
Catalog: Peptides
Create Date: 2018-06-09 15:43:13
Modify Date: 2024-01-08 23:28:40
SLLK, Control Peptide for TSP1 Inhibitor is a control peptide for LSKL (leucine-serine-lysine-leucine).

Name	(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-1,3-dihydroxy-propylidene]amino]-1-hydroxy-4-methyl-pentylidene]amino]-1-hydroxy-4-methyl-pentylidene]amino]hexanoic acid

Description	SLLK, Control Peptide for TSP1 Inhibitor is a control peptide for LSKL (leucine-serine-lysine-leucine).
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Cancer Peptides
In Vivo	TGF-β1 is significantly lower (0.10±0.01 pg/mL) in the plasma of mice receiving LSKL compared with that in plasma of mice receiving SLLK control peptide at day 42 (0.20±0.02 pg/mL; P=0.0001). mRNA expression is assessed in the suprarenal aortic lysates obtained from mice receiving SLLK and LSKL peptides[1]. Akita mice treated with 30 mg/kg LSKL have significantly increased nephrin expression, greater than twofold, compared with renal lysates from either saline controls or SLLK-treated mice[2].
Animal Admin	Sterile solutions of LSKL or SLLK peptide are made in stock solutions of 3.0 mg/mL (high dose) or 0.3 mg/mL (low dose) in sterile saline. The i.p. injection of LSKL, SLLK, or saline began 2 weeks after uninephrectomy and continues thrice weekly for 15 weeks. For the low-dosage treatment regimen, each group of 20 mice receives 3 mg/kg body weight of peptide (LSKL or SLLK) per injection or saline (100 μL/10 g body weight per injection). For the high-dosage treatment regimen, Akita mice ae given i.p. injections of LSKL or SLLK peptide at 30 mg/kg body weight per injection or saline (100 μL/10 g body weight per injection).
References	[1]. Krishna SM, et al. A peptide antagonist of thrombospondin-1 promotes abdominal aortic aneurysm progression in the angiotensin II-infused apolipoprotein-E-deficient mouse. Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):389-98. [2]. Lu A, et al. Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. Am J Pathol. 2011 Jun;178(6):2573-86.

Density	1.3±0.1 g/cm3
Boiling Point	690.1±65.0 °C at 760 mmHg
Molecular Formula	C₂₁H₄₁N₅O₆
Molecular Weight	459.580
Flash Point	371.2±34.3 °C
Exact Mass	459.305695
LogP	2.91
Vapour Pressure	0.0±4.9 mmHg at 25°C
Index of Refraction	1.565
Storage condition	2-8℃

464924-27-4	852690-80-3
301544-78-5	1315378-77-8
152787-59-2	355367-87-2
128201-89-8	862502-26-9
222018-18-0	133393-81-4
1158522-08-7	1804426-90-1
940364-43-2	134104-43-1
131615-57-1	1805254-92-5
6906-52-1	930439-75-1
1804657-36-0	1535422-15-1